Atenção!


O atendimento às questões referentes ao Repositório Institucional será interrompido entre os dias 20 de dezembro de 2025 a 4 de janeiro de 2026.

Pedimos a sua compreensão e aproveitamos para desejar boas festas!

Logo do repositório

A comprehensive model for assessing and classifying patients with thrombotic microangiopathy: the TMA-INSIGHT score

dc.contributor.authorAddad, Vanessa Vilani [UNESP]
dc.contributor.authorPalma, Lilian Monteiro Pereira
dc.contributor.authorVaisbich, Maria Helena
dc.contributor.authorPacheco Barbosa, Abner Mácola [UNESP]
dc.contributor.authorda Rocha, Naila Camila [UNESP]
dc.contributor.authorde Almeida Cardoso, Marilia Mastrocolla
dc.contributor.authorde Almeida, Juliana Tereza Coneglian
dc.contributor.authorde Paula de Sordi, Monica Ap
dc.contributor.authorMachado-Rugolo, Juliana
dc.contributor.authorArantes, Lucas Frederico
dc.contributor.authorde Andrade, Luis Gustavo Modelli [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionHealth Technology Assessment Center of Hospital das Clínicas - HCFMB
dc.date.accessioned2025-04-29T20:17:21Z
dc.date.issued2023-12-01
dc.description.abstractBackground: Thrombotic Microangiopathy (TMA) is a syndrome characterized by the presence of anemia, thrombocytopenia and organ damage and has multiple etiologies. The primary aim is to develop an algorithm to classify TMA (TMA-INSIGHT score). Methods: This was a single-center retrospective cohort study including hospitalized patients with TMA at a single center. We included all consecutive patients diagnosed with TMA between 2012 and 2021. TMA was defined based on the presence of anemia (hemoglobin level < 10 g/dL) and thrombocytopenia (platelet count < 150,000/µL), signs of hemolysis, and organ damage. We classified patients in eight categories: infections; Malignant Hypertension; Transplant; Malignancy; Pregnancy; Thrombotic Thrombocytopenic Purpura (TTP); Shiga toxin-mediated hemolytic uremic syndrome (STEC-SHU) and Complement Mediated TMA (aHUS). We fitted a model to classify patients using clinical characteristics, biochemical exams, and mean arterial pressure at presentation. Results: We retrospectively retrieved TMA phenotypes using automatic strategies in electronic health records in almost 10 years (n = 2407). Secondary TMA was found in 97.5% of the patients. Primary TMA was found in 2.47% of the patients (TTP and aHUS). The best model was LightGBM with accuracy of 0.979, and multiclass ROC-AUC of 0.966. The predictions had higher accuracy in most TMA classes, although the confidence was lower in aHUS and STEC-HUS cases. Conclusion: Secondary conditions were the most common etiologies of TMA. We retrieved comorbidities, associated conditions, and mean arterial pressure to fit a model to predict TMA and define TMA phenotypic characteristics. This is the first multiclass model to predict TMA including primary and secondary conditions.en
dc.description.affiliationDepartment of Internal Medicine - UNESP Univ Estadual Paulista, Rubião Jr, s/n
dc.description.affiliationDepartment of Pediatrics Universidade Estadual de Campinas, R. Tessália Vieira de Camargo, 126 - Cidade Universitária
dc.description.affiliationPediatric Nephrology Service Child Institute University of São Paulo, Av. Dr. Enéas Carvalho de Aguiar, 647, SP
dc.description.affiliationHealth Technology Assessment Center of Hospital das Clínicas - HCFMB
dc.description.affiliationUnespDepartment of Internal Medicine - UNESP Univ Estadual Paulista, Rubião Jr, s/n
dc.identifierhttp://dx.doi.org/10.1186/s12959-023-00564-6
dc.identifier.citationThrombosis Journal, v. 21, n. 1, 2023.
dc.identifier.doi10.1186/s12959-023-00564-6
dc.identifier.issn1477-9560
dc.identifier.scopus2-s2.0-85177560073
dc.identifier.urihttps://hdl.handle.net/11449/309963
dc.language.isoeng
dc.relation.ispartofThrombosis Journal
dc.sourceScopus
dc.subjectAtypical hemolytic uremic syndrome
dc.subjectComplement mediated TMA
dc.subjectShiga toxin-mediated hemolytic uremic syndrome
dc.subjectThrombotic microangiopathy
dc.subjectThrombotic Thrombocytopenic Purpura
dc.titleA comprehensive model for assessing and classifying patients with thrombotic microangiopathy: the TMA-INSIGHT scoreen
dc.typeArtigopt
dspace.entity.typePublication
unesp.author.orcid0000-0002-9322-3849[1]
unesp.author.orcid0000-0002-0334-8470[2]
unesp.author.orcid0000-0002-6084-7831[3]
unesp.author.orcid0000-0003-3668-8911[4]
unesp.author.orcid0000-0002-1684-2574[5]
unesp.author.orcid0000-0002-6231-5425[6]
unesp.author.orcid0000-0001-8865-0398[7]
unesp.author.orcid0000-0003-3621-3414[8]
unesp.author.orcid0000-0003-3984-4959[9]
unesp.author.orcid0000-0002-4946-5189[10]
unesp.author.orcid0000-0002-0230-0766[11]

Arquivos

Coleções